Earnings summaries and quarterly performance for NutriBand.
Research analysts covering NutriBand.
Recent press releases and 8-K filings for NTRB.
Nutriband Inc. Updates Shareholders on Annual Meeting Highlights
NTRB
Board Change
New Projects/Investments
Legal Proceedings
- Nutriband Inc. announced the appointment of Alessandro Puddu and Viorica Carlig as new directors to its board.
- The company provided a 2025 development summary and 2026 focus for its AVERSA™ FENTANYL product, including patent grants, manufacturing scale-up, and plans to file an Investigational New Drug (IND) application and initiate a Human Abuse Liability (HAL) clinical study.
- The full purchase price for the Pocono Pharma subsidiary sale has not been received, with Nutriband collecting $30,000 USD in penalties at a rate of $10,000 USD weekly for delayed closing.
- Nutriband filed a complaint with FINRA regarding suspected naked short selling and noted that 910,904 warrants with a strike price of $6.43, totaling $5,856,112 if exercised, will expire on October 1, 2026.
8 days ago
Nutriband Announces 2025 Achievements and 2026 Outlook
NTRB
Dividends
Convertible Preferred Issuance
New Projects/Investments
- Nutriband Inc. agreed to sell 90% of its Pocono subsidiary for $5M USD to EarthVision Bio, retaining 10% equity and adding $5M to its bottom line without shareholder dilution.
- In July 2025, the company announced a 25% Preferred Stock dividend, with each preferred share convertible to one common share following FDA approval of AVERSA Fentanyl.
- The company made significant strides in 2025 for its AVERSA™ Fentanyl product, including securing new U.S. patents, completing commercial manufacturing process scale-up, and obtaining a Type C Meeting with the US FDA.
- Nutriband was added to the Russell Microcap, Russell Microcap Growth, Russell 3000E, and Russell 3000E Growth Indexes in July 2025.
Dec 31, 2025, 12:00 PM
Nutriband Inc. to Sell Majority Stake in Pocono Pharmaceutical
NTRB
M&A
New Projects/Investments
- Nutriband Inc. (NTRB) has signed an agreement to sell a 90% interest in its subsidiary, Pocono Pharmaceutical, to EarthVision Bio for $5 million USD.
- The transaction is expected to close on December 31, 2025.
- Nutriband Inc. shareholders will retain a 10% shareholding in Earth Vision Bio following the acquisition.
- The proceeds from the sale will be used to fund the continued development of AVERSA Fentanyl, an abuse-deterrent opioid patch with potential annual US sales of $80 million to $200 million.
Dec 30, 2025, 9:28 PM
Nutriband Inc. Sells Majority Stake in Subsidiary Pocono Pharmaceutical
NTRB
M&A
New Projects/Investments
- Nutriband Inc. has signed an agreement to sell a 90% interest in its subsidiary Pocono Pharmaceutical to EarthVision Bio for $5 million USD.
- The transaction is expected to close on December 31, 2025.
- Nutriband Inc. shareholders will retain a 10% shareholding in EarthVision Bio following the acquisition.
- The proceeds from the sale will be used towards the continued development of AVERSA Fentanyl, which has the potential for $80 million to $200 million in annual US sales.
Dec 29, 2025, 2:00 PM
Nutriband Differentiates Fentanyl and Details Abuse-Deterrent Product Development
NTRB
New Projects/Investments
Product Launch
- Nutriband Inc. clarified that FDA-approved prescription fentanyl is distinct from illicit fentanyl, emphasizing its critical role in managing severe chronic pain, in response to the US government's designation of illicit fentanyl as a weapon of mass destruction.
- The company is developing Aversa™ Fentanyl, an abuse-deterrent transdermal system, by combining its proprietary Aversa™ technology with Kindeva’s FDA-approved fentanyl patch.
- Aversa™ Fentanyl has the potential to be the world's first abuse-deterrent opioid patch and is projected to achieve peak annual US sales of $80 million to $200 million.
- Nutriband's AVERSA™ abuse-deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries.
Dec 18, 2025, 12:00 PM
Nutriband Announces Successful FDA Meeting for Abuse Deterrent Fentanyl Patch
NTRB
Product Launch
New Projects/Investments
- Nutriband Inc. announced a successful meeting with the US FDA on September 18, 2025, regarding its lead product, AVERSA™ FENTANYL, an abuse deterrent fentanyl transdermal system.
- The FDA confirmed the regulatory pathway for AVERSA™ FENTANYL as a 505(b)(2) New Drug Application (NDA) and provided feedback on Chemistry, Manufacturing, and Controls (CMC) plans.
- Nutriband will proceed with an Investigational New Drug (IND) filing for a Human Abuse Potential clinical study, incorporating the FDA's feedback.
- AVERSA™ FENTANYL has the potential to be the first abuse deterrent fentanyl patch approved worldwide and is projected to reach peak annual US sales of $80 million to $200 million.
Oct 28, 2025, 4:00 PM
Nutriband Receives FDA Feedback for AVERSA™ FENTANYL Development
NTRB
New Projects/Investments
Product Launch
- Nutriband met with the US FDA on September 18, 2025, to obtain feedback on the Chemistry, Manufacturing, and Controls (CMC) plans for its lead product, AVERSA™ FENTANYL (abuse-deterrent fentanyl transdermal system).
- The FDA confirmed the regulatory pathway for the product is a 505(b)(2) New Drug Application (NDA) and provided guidance on the registration batch plan, manufacturing process validation strategy, and product specifications.
- Nutriband has received final meeting minutes and is incorporating the FDA's feedback into its development program as it moves towards an Investigational New Drug (IND) filing to support a Human Abuse Potential (HAP) clinical study.
- AVERSA™ FENTANYL has the potential to be the first abuse-deterrent fentanyl patch approved worldwide and is estimated to reach peak annual US sales of $80 million to $200 million.
Oct 28, 2025, 3:05 PM
Nutriband Receives Final FDA Feedback for AVERSA™ FENTANYL
NTRB
New Projects/Investments
Product Launch
- Nutriband received final meeting minutes from the US FDA following a September 18, 2025, meeting to discuss Chemistry, Manufacturing, and Controls (CMC) plans for its lead product, AVERSA™ FENTANYL (abuse deterrent fentanyl transdermal system).
- The company is incorporating the FDA's feedback into its development program as it moves towards an Investigational New Drug (IND) filing in support of a Human Abuse Potential (HAP) clinical study.
- The FDA confirmed the regulatory pathway for the product is a 505(b)(2) New Drug Application (NDA) and provided guidance on the registration batch plan, manufacturing process validation, and product specifications.
- Nutriband's abuse deterrent fentanyl patch has the potential to be the first approved worldwide, with estimated peak annual US sales ranging from $80 million to $200 million.
Oct 28, 2025, 11:00 AM
Nutriband Announces Gareth Sheridan's Return as CEO
NTRB
CEO Change
Management Change
- Nutriband Inc. announced that its founder, Gareth Sheridan, has returned as CEO, effective October 27, 2025.
- Sheridan will guide the company towards a target NDA filing in 2026 for AVERSA Fentanyl, an abuse-deterrent opioid patch.
- AVERSA Fentanyl has the potential to reach peak annual US sales of $80 million to $200 million.
- Co-Founder and Chairman Serguei Melnik had served as interim CEO from August 10 until October 27.
Oct 27, 2025, 11:00 AM
Nutriband Inc. Announces Warrant Exercise and Funding for AVERSA Fentanyl Development
NTRB
New Projects/Investments
- Nutriband Inc. announced the exercise of warrants at a strike price of $6.43.
- This exercise generated $5,306,000 in proceeds for the company.
- The primary use of these proceeds is for the remaining clinical development of AVERSA Fentanyl and the submission of its New Drug Application (NDA) with the FDA for marketing approval.
- AVERSA Fentanyl is estimated to have peak annual US sales ranging from $80 million to $200 million and has the potential to become the world's first opioid patch with abuse deterrent properties.
Sep 3, 2025, 8:01 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more